| 产品介绍 |
Ruxolitinib, also known as INC424 and INCB18424 or INCB018424, is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.
CAS号：941678-49-5
分子式：C17H18N6
分子量：306.37
MDL：MFCD12031592
纯度：≥98% (HPLC)
作用靶点：JAK; Autophagy; Mitophagy; Apoptosis;
作用通路：Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt; Autophagy; Apoptosis;
介绍：鲁索利替尼 (Ruxolitinib, INCB18424) 是有效的，选择性的 JAK1/2 抑制剂， IC50 值
|
